Pharma BD Deal Intelligence

Astellas Pharma Inc. / Ogeda SA

2017 · Acquisition/Merger · $850M · Complete

Announcement Sentiment

100

Strongly positive

Astellas agreed to acquire Ogeda for up to EUR 800M (~$850M), with EUR 500M (~$531M) upfront for 100% of equity and up to EUR 300M (~$319M) in clinical/regulatory milestones for fezolinetant. Fezolinetant is a selective NK3 receptor antagonist with positive Phase 2a data in menopause-related vasomotor symptoms.

Did it work? Outcome assessment

Strategic verdict

Achieved Stated Rationale

Financial impact

Neutral

Pipeline outcome

Assets Advanced

Assessment window: 5yr post-close.

Key facts

Announced Apr 02, 2017
Closed Apr 19, 2017
Deal value $850M
Deal type Acquisition/Merger
Therapeutic area Menopausal vasomotor symptoms (hot flashes); endometriosis; uterine fibroids
Indications Menopausal vasomotor symptoms (hot flashes); endometriosis; uterine fibroids
Key assets Fezolinetant (ESN364)
Mechanism Selective NK3 receptor antagonist

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals